- Allergan (NYSE:AGN) acquires privately held Boston, MA-based Topokine Therapeutics, a developer of topical medicines that act on subcutaneous fat to contour the face and body without surgery or injections. Its lead product candidate is XAF5 Ointment, in Phase 3 development for the treatment of bags under the eyes (steatoblepharon).
- Under the terms of the deal, Topokine will receive an upfront payment of $85M plus unspecified milestones related to XAF5.